Except complement C1q, the immunological functions of other C1q family members have remained unclear. In vitro studies showed that DrC1q-like could inhibit the apoptosis induced by ActD and CHX in EPC cells, through repressing the activation of caspase 3/9. Moreover, its physiological roles were studied by morpholino-mediated knockdown in zebrafish embryogenesis
C1q-like inhibits p53-mediated apoptosis and controls normal hematopoiesis during zebrafish embryogenesis.
No sample metadata fields
View SamplesPeptidoglycan recognition proteins (PGRPs) are a family of pattern recognition receptors (PRRs) that serve as a strong link between invertebrate and vertebrate immunity.It has been demonstrated that PGRPs in insects function as bacterial recognition molecules which trigger proteolytic or signal transduction pathways, being thus important in the antimicrobial innate immunity.
No associated publication
No sample metadata fields
View SamplesHuman prostate cancer tissues analyses
In silico dissection of cell-type-associated patterns of gene expression in prostate cancer.
No sample metadata fields
View SamplesThis SuperSeries is composed of the SubSeries listed below.
Integrative DNA methylation and gene expression analysis in high-grade soft tissue sarcomas.
Sex, Age
View SamplesThis SuperSeries is composed of the SubSeries listed below.
No associated publication
Specimen part, Disease, Disease stage
View SamplesAim to identify the potential relationship between DNA methylation and gene expression.
No associated publication
None
No sample metadata fields
View SamplesWe used the Infinium HumanHT-12 platform to profile gene expression in 79 primary, untreated high-grade soft tissue sarcomas, representing eight relevant subtypes, two non-neoplastic fat samples and 13 representative sarcoma cell lines.
Integrative DNA methylation and gene expression analysis in high-grade soft tissue sarcomas.
Sex
View SamplesThe objective is to generate a robust and validated predictor profile for chemotherapy response in patients with mCRC using microarray gene expression profiles of primary colorectal cancer tissue.
Gene expression profile predictive of response to chemotherapy in metastatic colorectal cancer.
Disease, Disease stage
View SamplesStudying the causes and correlates of natural variation in gene expression in healthy populations assumes that individual differences in gene expression can be reliably and stably assessed across time. However, this is yet to be established.
Assessing individual differences in genome-wide gene expression in human whole blood: reliability over four hours and stability over 10 months.
Sex, Age, Specimen part
View SamplesHairy cell leukemia (HCL) shows unique clinico-pathological and biological features. HCL responds well to purine analogues but relapses are frequent and novel therapies are required. BRAF-V600E is the key driver mutation in HCL and distinguishes it from other B-cell lymphomas, including HCL-like leukemias/lymphomas (HCL-variant and splenic marginal zone lymphoma). The kinase-activating BRAF-V600E mutation also represents an ideal therapeutic target in HCL. Here, we investigated the biological and therapeutic importance of the activated BRAF-MEK-ERK pathway in HCL by exposing in vitro primary leukemic cells purified from 26 patients to clinically available BRAF (Vemurafenib; Dabrafenib) or MEK (Trametinib) inhibitors. Results were validated in vivo in samples from Vemurafenib-treated HCL patients within a phase-2 clinical trial. BRAF and MEK inhibitors caused, specifically in HCL (but not HCL-like) cells, marked MEK/ERK dephosphorylation, silencing of the BRAF-MEK-ERK pathway transcriptional output, loss of the HCL-specific gene expression signature, downregulation of the HCL markers CD25, TRAP and cyclin-D1, smoothening of leukemic cells' hairy surface, and, eventually, apoptosis. Apoptosis was partially blunted by co-culture with bone marrow stromal cells antagonizing MEK-ERK dephosphorylation. This protective effect could be counteracted by combined BRAF and MEK inhibition. Our results strongly support and inform the clinical use of BRAF and MEK inhibitors in HCL.
BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity.
Specimen part, Treatment, Subject
View Samples